Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Steroid-Sparing cocktail tame chemo nausea?

NCT ID NCT07699276

Recruiting now Symptom relief Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study enrolls adults receiving their first cycle of cisplatin at a dose of at least 50 mg/m².

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
olanzapine and ondansetron (with dexamethasone sparing)
What this could lead to
If successful, this could offer a way to prevent chemotherapy-induced nausea and vomiting while reducing steroid use, potentially lowering side effects.
What could go wrong
This is a small, single-arm phase 2 study, so results may not apply broadly. The steroid-sparing approach might be less effective than standard care, and olanzapine can cause drowsiness or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER (SOLID TUMORS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER (SOLID TUMORS) CISPLATIN OLANZAPINE VOMITING

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Faculty of Medicine Siriraj Hospital, Mahidol University

    RECRUITING

    Bangkok, 10700, Thailand

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.